186 related articles for article (PubMed ID: 34407628)
1. Spillover of Medicaid Expansion to Prescribing of Opioid Use Disorder Medications in Medicare Part D.
Abraham AJ; Lawler EC; Harris SJ; Bagwell Adams G; Bradford WD
Psychiatr Serv; 2022 Apr; 73(4):418-424. PubMed ID: 34407628
[TBL] [Abstract][Full Text] [Related]
2. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
3. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
Abraham AJ; Adams GB; Bradford AC; Bradford WD
Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
[TBL] [Abstract][Full Text] [Related]
4. Impact of Medicaid Expansion on Access to Opioid Analgesic Medications and Medication-Assisted Treatment.
Sharp A; Jones A; Sherwood J; Kutsa O; Honermann B; Millett G
Am J Public Health; 2018 May; 108(5):642-648. PubMed ID: 29565661
[TBL] [Abstract][Full Text] [Related]
5. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D.
Strickland JC; Huhn AS; Bergeria CL; Strain EC; Dunn KE
J Addict Med; 2021 Jul-Aug 01; 15(4):325-333. PubMed ID: 33156180
[TBL] [Abstract][Full Text] [Related]
6. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
[TBL] [Abstract][Full Text] [Related]
7. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
Saloner B; Levin J; Chang HY; Jones C; Alexander GC
JAMA Netw Open; 2018 Aug; 1(4):e181588. PubMed ID: 30646116
[TBL] [Abstract][Full Text] [Related]
8. Medicaid Expansion and Availability of Opioid Medications in the Specialty Substance Use Disorder Treatment System.
Abraham AJ; Yarbrough CR; Harris SJ; Adams GB; Andrews CM
Psychiatr Serv; 2021 Feb; 72(2):148-155. PubMed ID: 33267651
[TBL] [Abstract][Full Text] [Related]
9. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.
Wen H; Hockenberry JM; Borders TF; Druss BG
Med Care; 2017 Apr; 55(4):336-341. PubMed ID: 28296674
[TBL] [Abstract][Full Text] [Related]
10. Opioid Prescribing Practices of Neurosurgeons: Analysis of Medicare Part D.
Khalid SI; Adogwa O; Lilly DT; Desai SA; Vuong VD; Mehta AI; Cheng J
World Neurosurg; 2018 Apr; 112():e31-e38. PubMed ID: 29253702
[TBL] [Abstract][Full Text] [Related]
11. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
12. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
Parish WJ; Mark TL; Zarkin GA; Weber E
Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.
Treitler P; Nowels M; Samples H; Crystal S
JAMA Netw Open; 2023 May; 6(5):e2312030. PubMed ID: 37145594
[TBL] [Abstract][Full Text] [Related]
14. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
Nguyen T; Andraka-Christou B; Simon K; Bradford WD
J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
[TBL] [Abstract][Full Text] [Related]
15. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
[TBL] [Abstract][Full Text] [Related]
16. The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.
Knudsen HK; Hartman J; Walsh SL
Drug Alcohol Depend; 2022 Mar; 232():109336. PubMed ID: 35123365
[TBL] [Abstract][Full Text] [Related]
17. Emergency Providers' Opioid Prescribing Behaviors Among Medicare Part D Beneficiaries in North Carolina, 2013-2014: Medication Utilization and Costs.
Williams B; Mospan G; Seabock R; Gillette C; DeGeeter M
N C Med J; 2018; 79(3):143-148. PubMed ID: 29735614
[No Abstract] [Full Text] [Related]
18. Association of Medicaid Expansion With Opioid Overdose Mortality in the United States.
Kravitz-Wirtz N; Davis CS; Ponicki WR; Rivera-Aguirre A; Marshall BDL; Martins SS; Cerdá M
JAMA Netw Open; 2020 Jan; 3(1):e1919066. PubMed ID: 31922561
[TBL] [Abstract][Full Text] [Related]
19. Characterizing Opioid Prescribing Trends of Medical Oncologists From 2013 to 2019: Analysis From the Centers for Medicare & Medicaid Services Medicare Part D Prescribers Database.
Korst MR; Santos Teles M; Choudhry HS; Santitoro JG; Garcia DJ; Schwab SMT; Kra JA
JCO Oncol Pract; 2024 Feb; 20(2):268-277. PubMed ID: 38061003
[TBL] [Abstract][Full Text] [Related]
20. Analysis of psychiatrists' prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States.
Pan K; Silver S; Davis C
Trends Psychiatry Psychother; 2020; 42(1):48-54. PubMed ID: 32321084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
